Perioperative management of biologic disease-modifying antirheumatic drugs in patients with inflammatory rheumatic diseases undergoing total joint arthroplasty: A nationwide population-based cohort study from Taiwan
Background: The optimal perioperative management of biologic disease-modifying antirheumatic drugs (bDMARDs) in inflammatory rheumatic disease (IRD) patients undergoing total joint arthroplasty (TJA) remains debated, with current guidelines based on low-to-moderate quality evide…